AstraZeneca is a multinational pharmaceutical and biotechnology company recognized for Research and Development and Safety in the 2022 Clinical Trials Arena Excellence Awards.
Perhaps the most notable R&D efforts that the company has made recently have been in the realm of COVID-related trials. The company has developed a vaccine and several drug candidates, some of which have proven their safety and effectiveness in Phase III trials. The company has also focused on respiratory illnesses in general with an example being its nirsevimab drug, developed jointly with Sanofi.
Go deeper with GlobalData
Oncology has been another active area with the company participating in several ongoing trials for breast, lung and kidney cancer, as well as gliomal. In this field the company has struck partnerships with Merck, HUTCHMED and Daiichi Sankyo.
The company has also been active in the fields of asthma treatments, dermatology and urology and has also trialled some promising drug combinations in collaboration with Care Access Research.
Company Profile
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases.
The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices.
The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
